Robin S. Goland, MD

Articles by Robin S. Goland, MD

Strategies to Improve Screening and Diagnosis of T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 24th 2023

Drs Robert Busch, Robin S. Goland, Kimberly Simmons, and Teresa Quattrin discuss strategies to facilitate screening of type 1 diabetes and improve management of disease.

Managing T1D Comorbidities

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 24th 2023

Experts in endocrinology share their approach to managing type 1 diabetes along with related health conditions.

Investigational Therapies for the Management of T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 17th 2023

Teresa Quattrin, MD, reviews emerging clinical trial data on novel therapies to delay the progression of type 1 diabetes.

Patient Monitoring After Teplizumab Therapy in T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 17th 2023

Kimberly Simmons, MD, MPH/MSPH, leads a discussion on long-term monitoring for patients with type 1 diabetes and which providers are most likely to administer and manage teplizumab treatment.

Patient Selection for Teplizumab in T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 13th 2023

Experts in endocrinology share their approach to patient selection for teplizumab in type 1 diabetes and the impact of a 2-year delay in the onset of the disease.

Safety and Efficacy of Teplizumab in T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 13th 2023

Dr Kimberly Simmons reviews key findings from an initial study and extended follow-up on the safety and efficacy of teplizumab in delaying the progression of type 1 diabetes.

New Therapies to Delay T1D Progression

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 8th 2023

Robin S. Goland, MD, and Kimberly Simmons, MD, MPH/MSPH, provide insight on teplizumab, which was recently approved by the FDA, to delay the progression of type 1 diabetes, and they discuss the implications of autoantibody detection in patients.